Table 2:

Activity outcomes

	Efficacy-evaluable population* (n=54)	Patients with baseline CNS disease† (n=12)	Patients with no baseline CNS disease*† (n=42)
Proportion of patients achieving a response	31 (57%)	6 (50%)	25 (60%)
Best overall response
Complete response	4 (7%)	0	4 (10%)
Partial response	27 (50%)	6 (50%)	21 (50%)
Stable disease	9 (17%)	4 (33%)	5 (12%)
Progressive disease	4 (7%)	0	4 (10%)
Non-complete response or progressive disease	3 (6%)	0	3 (7%)
Missing or unevaluable‡	7 (13%)	2 (17%)	5 (12%)
Median duration of response, months	10·4 (7·1-NE)	NE	12·9 (7·1-NE)
Median progression-free survival, months	11·2 (8·0–14·9)	7·7 (4·7-NE)	12·0 (8·7–15·7)

Data are n (%) or median (95% CI). NE=not estimable.

^*Systemic response.

^†CNS disease status determined by the investigator.

^‡Missing or unevaluable included patients with no post-baseline scans available, missing subsets of scans at all time points, or patients who discontinued before obtaining adequate scans to evaluate or confirm response.